Anne Auperin

Institut de Cancérologie Gustave Roussy, Villejuif, Île-de-France, France

Are you Anne Auperin?

Claim your profile

Publications (160)993.07 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even higher incidence in adolescents, and is primarily represented by only a few histologic subtypes. Dramatic progress has been achieved, with survival rates exceeding 80%, in large part because of a better understanding of the biology of the different subtypes and national and international collaborations. Most patients with Burkitt lymphoma and diffuse large B-cell lymphoma are cured with short intensive pulse chemotherapy containing cyclophosphamide, cytarabine, and high-dose methotrexate. The benefit of the addition of rituximab has not been established except in the case of primary mediastinal B-cell lymphoma. Lymphoblastic lymphoma is treated with intensive, semi-continuous, longer leukemia-derived protocols. Relapses in B-cell and lymphoblastic lymphomas are rare and infrequently curable, even with intensive approaches. Event-free survival rates of approximately 75% have been achieved in anaplastic large-cell lymphomas with various regimens that generally include a short intensive B-like regimen. Immunity seems to play an important role in prognosis and needs further exploration to determine its therapeutic application. ALK inhibitor therapeutic approaches are currently under investigation. For all pediatric lymphomas, the intensity of induction/consolidation therapy correlates with acute toxicities, but because of low cumulative doses of anthracyclines and alkylating agents, minimal or no long-term toxicity is expected. Challenges that remain include defining the value of prognostic factors, such as early response on positron emission tomography/computed tomography and minimal disseminated and residual disease, using new biologic technologies to improve risk stratification, and developing innovative therapies, both in the first-line setting and for relapse. © 2015 by American Society of Clinical Oncology.
    Journal of Clinical Oncology 08/2015; 33(27). DOI:10.1200/JCO.2014.59.5827 · 18.43 Impact Factor

  • Annals of Oncology 07/2015; 26(10). DOI:10.1093/annonc/mdv301 · 7.04 Impact Factor
  • F. Fayard · A. Aupérin · A. Laplanche · J.-P. Pignon ·

    Revue d Épidémiologie et de Santé Publique 05/2015; 63. DOI:10.1016/j.respe.2015.03.008 · 0.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the effects of administering chemotherapy following surgery, or following surgery plus radiotherapy (known as adjuvant chemotherapy) in patients with early stage non-small cell lung cancer (NSCLC),we performed two systematic reviews and meta-analyses of all randomised controlled trials using individual participant data. Results were first published in The Lancet in 2010. To compare, in terms of overall survival, time to locoregional recurrence, time to distant recurrence and recurrence-free survival:A. Surgery versus surgery plus adjuvant chemotherapyB. Surgery plus radiotherapy versus surgery plus radiotherapy plus adjuvant chemotherapyin patients with histologically diagnosed early stage NSCLC.(2)To investigate whether or not predefined patient subgroups benefit more or less from cisplatin-based chemotherapy in terms of survival. We supplemented MEDLINE and CANCERLIT searches (1995 to December 2013) with information from trial registers, handsearching relevant meeting proceedings and by discussion with trialists and organisations. We included trials of a) surgery versus surgery plus adjuvant chemotherapy; and b) surgery plus radiotherapy versus surgery plus radiotherapy plus adjuvant chemotherapy, provided that they randomised NSCLC patients using a method which precluded prior knowledge of treatment assignment. We carried out a quantitative meta-analysis using updated information from individual participants from all randomised trials. Data from all patients were sought from those responsible for the trial. We obtained updated individual participant data (IPD) on survival, and date of last follow-up, as well as details of treatment allocated, date of randomisation, age, sex, histological cell type, stage, and performance status. To avoid potential bias, we requested information for all randomised patients, including those excluded from the investigators' original analyses. We conducted all analyses on intention-to-treat on the endpoint of survival. For trials using cisplatin-based regimens, we carried out subgroup analyses by age, sex, histological cell type, tumour stage, and performance status. We identified 35 trials evaluating surgery plus adjuvant chemotherapy versus surgery alone. IPD were available for 26 of these trials and our analyses are based on 8447 participants (3323 deaths) in 34 trial comparisons. There was clear evidence of a benefit of adding chemotherapy after surgery (hazard ratio (HR)= 0.86, 95% confidence interval (CI)= 0.81 to 0.92, p< 0.0001), with an absolute increase in survival of 4% at five years.We identified 15 trials evaluating surgery plus radiotherapy plus chemotherapy versus surgery plus radiotherapy alone. IPD were available for 12 of these trials and our analyses are based on 2660 participants (1909 deaths) in 13 trial comparisons. There was also evidence of a benefit of adding chemotherapy to surgery plus radiotherapy (HR= 0.88, 95% CI= 0.81 to 0.97, p= 0.009). This represents an absolute improvement in survival of 4% at five years.For both meta-analyses, we found similar benefits for recurrence outcomes and there was little variation in effect according to the type of chemotherapy, other trial characteristics or patient subgroup.We did not undertake analysis of the effects of adjuvant chemotherapy on quality of life and adverse events. Quality of life information was not routinely collected during the trials, but where toxicity was assessed and mentioned in the publications, it was thought to be manageable. We considered the risk of bias in the included trials to be low. Results from 47 trial comparisons and 11,107 patients demonstrate the clear benefit of adjuvant chemotherapy for these patients, irrespective of whether chemotherapy was given in addition to surgery or surgery plus radiotherapy. This is the most up-to-date and complete systematic review and individual participant data (IPD) meta-analysis that has been carried out.
    Cochrane database of systematic reviews (Online) 03/2015; 3:CD011430. DOI:10.1002/14651858.CD011430 · 6.03 Impact Factor
  • Source
    F Bidault · S Ammari · V Roche · S Dreuil · N Lassau · S Temam · A Aupérin · C Dromain · F Rotolo ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Evaluation of the qualitative improvement in the visualisation of head and neck carcinoma obtained by dual-energy CT via material density iodine-water images as compared to conventional CT Any information contained in this pdf file is automatically generated from digital material submitted to EPOS by third parties in the form of scientific presentations. References to any names, marks, products, or services of third parties or hypertext links to third-party sites or information are provided solely as a convenience to you and do not in any way constitute or imply ECR's endorsement, sponsorship or recommendation of the third party, information, product or service. ECR is not responsible for the content of these pages and does not make any representations regarding the content or accuracy of material in this file. As per copyright regulations, any unauthorised use of the material or parts thereof as well as commercial reproduction or multiple distribution by any traditional or electronically based reproduction/publication method ist strictly prohibited. You agree to defend, indemnify, and hold ECR harmless from and against any and all claims, damages, costs, and expenses, including attorneys' fees, arising from or related to your use of these pages. Please note: Links to movies, ppt slideshows and any other multimedia files are not available in the pdf version of presentations. Squamous cell carcinoma is the most frequent of head and neck cancers. Computed tomography (CT) is widely recommended for initial staging. Dual energy computed tomography (DECT) technology has been implemented in some commercial CT devices for the last several years. DECT uses several technical approaches depending on manufacturer, and post-processing can provide a variety of types of images or maps [1, 2]. Among these maps is a set of images called the "Material density iodine-water" map. The present study uses the material density iodine-water map to evaluate the qualitative improvement in the visualization of head and neck squamous cell carcinoma provided by DECT as compared to CT.
    ECR 2015 - European Congress of Radiology, Vienna (Austria); 03/2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To describe relapsed B-cell lymphoma or leukemia in children/adolescents treated with a "Lymphomes Malins B" regimen and their outcome and to identify survival prognostic factors, relapses in the LMB89, 96 and 2001 studies of the Société Française d'Oncologie Pédiatrique (Société Française des Cancers de l'Enfant) were reviewed. Therapeutic guidelines at relapse were to obtain a second complete remission and to consolidate with high-dose chemotherapy followed by autologous stem-cell transplantation. Between July 1989 and March 2007, 67 patients of 1322 (5%) relapsed: 57 had Burkitt and 10 large-cell histology. Three patients were initially treated in risk Group A, 41 in Group B and 23 in Group C. Thirty-three patients had a relapse in one site (15 in the central nervous system) and 34 at multiple sites. Sixty-five patients received salvage chemotherapy and 33 achieved complete remission. Forty-one patients also received high-dose chemotherapy followed by autologous (n=33) or allogeneic (n=8) transplant. With a median follow-up of 6.4 years, the 5-year survival rate was 29.9%. Nineteen patients were still alive, all but one (Group A) received consolidation treatment. Multivariate analysis showed the following factors to be significantly associated with better survival: relapse at one site (p=0.0006), large-cell histology (p=0.012), initial prognostic Group A or B with LDH below twice the normal value (p=0.005), and time to relapse later than 6 months (p=0.04). Copyright © 2015, Ferrata Storti Foundation.
    Haematologica 02/2015; 100(6). DOI:10.3324/haematol.2014.121434 · 5.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Minimal invasive methods are needed as an alternative to surgery for treatment of lung metastases. The prospective data base of two cancer centers including all consecutive patients treated with radiofrequency ablation (RFA) for lung metastasis over 8 years was reviewed. RFA was performed under general anesthesia, with CT-guidance using a 15-gauge multi-tined expandable electrodes RF needle. 566 patients including 290 men (51%), 62.7 ±13.2 years old with primary tumor to the colon (34%), rectum (18%), kidney (12%), soft tissue (9%), and miscellaneous (27%) received 642 RFA for 1037 lung metastases. 53% of patients had 1 metastasis, 25% had 2, 14% had 3, 5% had 4, 4% had 5 to 8. Metastases were unilateral (75%), or bilateral (25%). The median diameter [extremes] of metastases was 15 mm [4-70]. 22% of patients had extra-pulmonary disease amenable to local therapy including 49 liver, 16 bone, 60 miscellaneous metastases. Median follow-up was 35.5 months. Median OS was 62 months. 4year-local efficacy was 89%. 4 year-lung disease control rate was 44.1%, with patient retreated safely up to 4 times. Primary origin, disease free interval, size and number of metastases were associated with OS in multivariate analysis. Progression at RFA site was associated with poor OS [p=0.011, HR:1.69 (95%CI=1.13-2.54)]. In the 293 colorectal cancer metastases, size >2cm (HR=2.10, p=0.0027) and a number of metastases ≥3 (HR=1.86, p=0.011) remained significantly associated with OS. A prognostic score made of 3 groups based on the 4 above-mentioned prognostic factors demonstrated 3-year OS rates of respectively 82.2%, 69.5% and 53.6% (logrank test, p=<0.0001) among the 3 groups in the overall population, and of 81.3%, 72.8%, and 57.9% (logrank test, p=0.005) in the colorectal cancer patients. Radiofrequency is an option for treatment of small size lung metastases, namely the ones below 2 to 3 cm. © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
    Annals of Oncology 02/2015; 26(5). DOI:10.1093/annonc/mdv037 · 7.04 Impact Factor

  • J. Guigay · U. Keilholz · R. Mesia · N. Vintonenko · J. Bourhis · A. Auperin ·

  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To evaluate the survival outcomes of percutaneous thermal ablation (RFA + microwaves) for patients presenting N0 non-small-cell lung cancer (NSCLC) ineligible for surgery. Materials and methods: Eighty-seven patients from two comprehensive cancer centers were included. Eighty-two patients were treated with RFA electrodes and five with microwave antenna. Overall survival (OS) and disease-free survival (DFS) were estimated and predictive factors of local tumor progression, OS and DFS identified and compared by univariate and multivariate analyses Results: Median follow-up was 30.5 months (interquartile range 16.7-51) and tumor size was 21 mm (range 10-54 mm). Treatment was incomplete for 14 patients with a local tumor progression of 11.5, 18.3, and 21.1 % at 1, 2, and 3 years, respectively. Two patients presented with neurological (grade III or IV) complications, and one died of respiratory and multivisceral failure as a result of the procedure at 29 days. In univariate analysis, increasing tumor size (P = 0.003) was the only predictive factor related to risk of local tumor progression. 5-year OS and DFS were 58.1 and 27.9 %, respectively. Sex (P = 0.044), pathology (P = 0.032), and tumor size >2 cm (P = 0.046) were prognostic factors for DFS. In multivariate analysis, pathology (P = 0.033) and tumor size >2 cm (P = 0.032) were independent prognostic factors for DFS. Conclusions: Oversized and overlapping ablation of N0 NSCLC was well tolerated, effective, with few local tumor progressions, even over long-term follow-up. Increasing tumor size was the main prognostic factor linked to OS, DFS, and local tumor progression.
    CardioVascular and Interventional Radiology 11/2014; 38(1). DOI:10.1007/s00270-014-0999-6 · 2.07 Impact Factor

  • Journal of Geriatric Oncology 10/2014; 5:S41. DOI:10.1016/j.jgo.2014.09.065 · 1.86 Impact Factor

  • 39th ESMO Congress (ESMO); 09/2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose This study examines the role of 18F-labeled fluorodeoxyglucose positron emission tomography (FDG-PET) in the implementation of involved-node radiation therapy (INRT) in patients treated for clinical stages (CS) I/II supradiaphragmatic Hodgkin lymphoma (HL). Methods and Material Patients with untreated CS I/II HL enrolled in the randomized EORTC/LYSA/FIL Intergroup H10 trial and participating in a real-time prospective quality assurance program were prospectively included in this study. Data were electronically obtained from 18 French cancer centers. All patients underwent APET-computed tomography (PET-CT) and a post-chemotherapy planning CT scanning. The pre-chemotherapy gross tumor volume (GTV) and the postchemotherapy clinical target volume (CTV) were first delineated on CT only by the radiation oncologist. The planning PET was then co-registered, and the delineated volumes were jointly analyzed by the radiation oncologist and the nuclear medicine physician. Lymph nodes undetected on CT but FDG-avid were recorded, and the previously determined GTV and CTV were modified according to FDG-PET results. Results From March 2007 to February 2010, 135 patients were included in the study. PET-CT identified at least 1 additional FDG-avid lymph node in 95 of 135 patients (70.4%; 95% confidence interval [CI]: 61.9%-77.9%) and 1 additional lymph node area in 55 of 135 patients (40.7%; 95% CI: 32.4%-49.5%). The mean increases in the GTV and CTV were 8.8% and 7.1%, respectively. The systematic addition of PET to CT led to a CTV increase in 60% of the patients. Conclusions Pre-chemotherapy FDG-PET leads to significantly better INRT delineation without necessarily increasing radiation volumes.
    International journal of radiation oncology, biology, physics 08/2014; 89(5):1047–1052. DOI:10.1016/j.ijrobp.2014.04.026 · 4.26 Impact Factor

  • The Lancet 07/2014; 384(9939):233. DOI:10.1016/S0140-6736(14)61209-5 · 45.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To investigate predictive factors for liver necrosis after transcatheter arterial chemoembolization (TACE) of neuroendocrine liver metastases. Methods: A total of 164 patients receiving 374 TACE were reviewed retrospectively to analyze predictive factors of liver necrosis. We analyzed patient age and sex; metastasis number and location; percentage of liver involvement; baseline liver function test; and pretreatment imaging abnormalities such as bile duct dilatation (BDD), portal vein narrowing (PVN), and portal vein thrombosis (PVT). We analyzed TACE technique such as Lipiodol or drug-eluting beads (DEB) as the drug's vector; dose of chemotherapy; diameter of DEB; and number, frequency, and selectivity of TACE. Results: Liver necrosis developed after 23 (6.1 %) of 374 TACE. In multivariate analysis, DEB > 300 μm in size induced more liver necrosis compared to Lipiodol (odds ratio [OR] 35.20; p < 0.0001) or with DEB < 300 μm in size (OR 19.95; p < 0.010). Pretreatment BDD (OR 119.64; p < 0.0001) and PVT (OR 9.83; p = 0.030) were predictive of liver necrosis. BDD or PVT responsible for liver necrosis were present before TACE in 59 % (13 of 22) and were induced by a previous TACE in 41 % (9 of 22) of cases. Conclusion: DEB > 300 μm in size, BDD, and PVT are responsible for increased rate of liver necrosis after TACE. Careful analysis of BDD or PVT on pretreatment images as well as images taken between two courses can help avoid TACE complications.
    CardioVascular and Interventional Radiology 05/2014; 38(2). DOI:10.1007/s00270-014-0914-1 · 2.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thermal ablation techniques (radiofrequency-ablation/cryotherapy) can be indicated with a curative intent. The success rate and prognostic factors for complete treatment were analysed. The medical records of all patients who had undergone curatively intended thermal ablation of bone metastases between September 2001 and February 2012 were retrospectively analysed. The goal was to achieve complete treatment of all bone metastases in patients with oligometastatic disease (group 1) or only of bone metastases that could potentially lead to skeletal-related events in patients with a long life expectancy (group 2). We report the rate of complete treatment according to patient characteristics, primary tumour site, bone metastasis characteristics, radiofrequency ablation/cryotherapy and the treatment group (group 1/group 2). Eighty-nine consecutive patients had undergone curatively intended thermal ablation of 122 bone metastases. The median follow-up was 22.8 months [IQR = 12.2-44.4]. In the intent-to-treat analysis, the 1-year complete treatment rate was 67 % (95%CI: 50 %-76 %). In the multivariate analysis the favourable prognostic factors for complete local treatment were oligometastatic status (p = 0.02), metachronous (p = 0.004) and small-sized (p = 0.001) bone metastases, without cortical bone erosion (p = 0.01) or neurological structures in the vicinity (p = 0.002). Thermal ablation should be included in the therapeutic arsenal for the cure of bone metastases. aEuro cent Thermal ablation techniques are currently performed to palliate pain caused by bone metastases. aEuro cent In selected patients, thermal ablation can also be indicated with a curative intent. aEuro cent Oligometastatic and/or metachronous diseases are good prognostic factors for local success. aEuro cent Small-size (< 2 cm) bone metastases and no cortical erosion are good prognostic factors.
    European Radiology 05/2014; 24(8). DOI:10.1007/s00330-014-3202-1 · 4.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Individual participant data meta-analyses of postoperative chemotherapy have shown improved survival for patients with non-small-cell lung cancer (NSCLC). We aimed to do a systematic review and individual participant data meta-analysis to establish the effect of preoperative chemotherapy for patients with resectable NSCLC. Methods We systematically searched for trials that started after January, 1965. Updated individual participant data were centrally collected, checked, and analysed. Results from individual randomised controlled trials (both published and unpublished) were combined using a two-stage fixed-effect model. Our primary outcome, overall survival, was defined as the time from randomisation until death (any cause), with living patients censored on the date of last follow-up. Secondary outcomes were recurrence-free survival, time to locoregional and distant recurrence, cause-specific survival, complete and overall resection rates, and postoperative mortality. Prespecified analyses explored any variation in effect by trial and patient characteristics. All analyses were by intention to treat. Findings Analyses of 15 randomised controlled trials (2385 patients) showed a significant benefit of preoperative chemotherapy on survival (hazard ratio [HR] 0.87, 95% CI 0.78-0.96, p=0.007), a 13% reduction in the relative risk of death (no evidence of a difference between trials; p=0.18, I-2 =25%). This finding represents an absolute survival improvement of 5% at 5 years, from 40% to 45%. There was no clear evidence of a difference in the effect on survival by chemotherapy regimen or scheduling, number of drugs, platinum agent used, or whether postoperative radiotherapy was given. There was no clear evidence that particular types of patient defined by age, sex, performance status, histology, or clinical stage benefited more or less from preoperative chemotherapy. Recurrence-free survival (HR 0.85, 95% CI 0.76-0.94, p=0.002) and time to distant recurrence (0.69, 0.58-0.82, p<0.0001) results were both significantly in favour of preoperative chemotherapy although most patients included were stage IB-IIIA. Results for time to locoregional recurrence (0.88, 0.73-1.07, p=0.20), although in favour of preoperative chemotherapy, were not statistically significant. Interpretation Findings, which are based on 92% of all patients who were randomised, and mainly stage IB-IIIA, show preoperative chemotherapy significantly improves overall survival, time to distant recurrence, and recurrence-free survival in resectable NSCLC. The findings suggest this is a valid treatment option for most of these patients. Toxic effects could not be assessed.
    The Lancet 05/2014; 383(9928):1561-1571. DOI:10.1016/S0140-6736(13)62159-5 · 45.22 Impact Factor

Publication Stats

5k Citations
993.07 Total Impact Points


  • 1996-2015
    • Institut de Cancérologie Gustave Roussy
      • • Department of Radiotherapy
      • • Department of Medical Imaging
      Villejuif, Île-de-France, France
    • Institut Curie
      • Service de Radiothérapie
      Lutetia Parisorum, Île-de-France, France
  • 2012
    • Université Paris-Sud 11
      Orsay, Île-de-France, France
    • Assistance Publique – Hôpitaux de Paris
      Lutetia Parisorum, Île-de-France, France
  • 2011
    • Centre Henri Becquerel
      Rouen, Haute-Normandie, France
  • 2010
    • Duke University
      Durham, North Carolina, United States
  • 2007
    • Hôpital Européen Georges-Pompidou (Hôpitaux Universitaires Paris-Ouest)
      Lutetia Parisorum, Île-de-France, France